Abilify and Interstitial lung disease - a phase IV clinical study of FDA data

Summary:

Interstitial lung disease is reported as a side effect among people who take Abilify (aripiprazole), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Effexor, and have Sleep disorder.

The phase IV clinical study analyzes which people have Interstitial lung disease when taking Abilify. It is created by eHealthMe based on reports of 97,308 people who have side effects when taking Abilify from the FDA, and is updated regularly.

What is Abilify?

Abilify has active ingredients of aripiprazole. It is often used in depression. eHealthMe is studying from 101,455 Abilify users. Check the latest studies of Abilify.

What is Interstitial lung disease?

Interstitial lung disease is found to be associated with 1,499 drugs and 1,841 conditions by eHealthMe. Check the latest studies of Interstitial lung disease.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 22, 2026

97,308 people reported to have side effects when taking Abilify.
Among them, 78 people (0.08%) have Interstitial lung disease.

Could Abilify cause Interstitial lung disease?

Among these 78 people:

How long have people been on Abilify when they have Interstitial lung disease? *

What is the gender of people who have Interstitial lung disease when taking Abilify? *

female: 64 %
male: 36 %

What is the age of people who have Interstitial lung disease when taking Abilify? *

What are other drugs people take besides Abilify? *

What are other side effects people have besides Interstitial lung disease? *

Pneumonia: 15 people, 19.23%
Intestinal Obstruction: 13 people, 16.67%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 12 people, 15.38%
Sarcoidosis (an inflammatory disease that affects multiple organs in the body, but mostly the lungs and lymph glands): 12 people, 15.38%
Chest Pain: 11 people, 14.10%
Bone Density Decreased: 10 people, 12.82%
Blood Iron Decreased: 10 people, 12.82%
Diarrhea: 10 people, 12.82%
Back Pain: 10 people, 12.82%
Fatigue (feeling of tiredness): 9 people, 11.54%

What are the existing conditions these people have? *

Sleep Disorder: 12 people, 15.38%
Diabetes: 11 people, 14.10%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 11 people, 14.10%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 9 people, 11.54%
High Blood Pressure: 8 people, 10.26%
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection): 8 people, 10.26%
Insomnia (sleeplessness): 5 people, 6.41%
Idiopathic Pulmonary Fibrosis (chronic lung disease): 4 people, 5.13%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 5.13%
Immunodeficiency Common Variable: 4 people, 5.13%

* Approximation only. Some reports may have incomplete information.

Do you take Abilify and have Interstitial lung disease?

- Check whether Interstitial lung disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Abilify:

Abilify (101,455 reports)

Browse all side effects of Abilify:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Interstitial lung disease:

Interstitial lung disease (1,499 drugs)

Browse all the conditions that are associated with Interstitial lung disease:

Interstitial lung disease (1,841 conditions)

Related publications that referenced our studies

Cetin, M., Celik, M., Cakici, M., Polat, M., & Suner, A, "Aripiprazole-Induced Hoarseness", Turk Psikiyatri Dergisi, 2018 Jan .
Thangakunam B, Christopher DJ, Mathews V, Srivastava A, "Mesenchymal stromal stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up", Lung India: official organ of Indian Chest Society, 2015 Jan .
Cetin M, Celik M, Cakici M, Polat M, Suner A, "Aripiprazole induced non-cardiogenic pulmonary edema: a case report", Turk Psikiyatri Dergisi, 2014 Dec .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .
Cetin, M., Celik, M., Cakici, M., Polat, M., & Suner, A, "Aripiprazole-Induced Hoarseness", Turk Psikiyatri Dergisi, 2018 Jan .
Thangakunam B, Christopher DJ, Mathews V, Srivastava A, "Mesenchymal stromal stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up", Lung India: official organ of Indian Chest Society, 2015 Jan .
Cetin M, Celik M, Cakici M, Polat M, Suner A, "Aripiprazole induced non-cardiogenic pulmonary edema: a case report", Turk Psikiyatri Dergisi, 2014 Dec .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on aripiprazole (the active ingredients of Abilify) and Abilify (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.